Full Text View  
  Tabular View  
  Contacts and Locations  
  No Study Results Posted  
  Related Studies  
Effect af Vitamin D Treatment in Primary Hyperparathyroidism
This study is currently recruiting participants.
Verified by University of Aarhus, December 2008
Sponsored by: University of Aarhus
Information provided by: University of Aarhus
ClinicalTrials.gov Identifier: NCT00674154
  Purpose

The primary aim of the study is to assess whether 6-months of vitamin D supplements prior to surgery decreases the risk of postoperative hypocalcaemia in patients with PHPT. Secondary endpoints include effects of vitamin D supplements on bone turnover, BMD, quality of life, overall well-being, and muscle function.


Condition Intervention Phase
Vitamin D Deficiency
Primary Hyperparathyroidism
Hypercalcemia
Drug: Cholecalciferol
Phase I

Drug Information available for: Vitamin D Ergocalciferol Cholecalciferol
U.S. FDA Resources
Study Type: Interventional
Study Design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment
Official Title: Effect of Vitamin D Treatment in Primary Hyperparathyroidism

Further study details as provided by University of Aarhus:

Primary Outcome Measures:
  • Fall in P-PTH [ Time Frame: One year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Improved muscular function [ Time Frame: One Year ] [ Designated as safety issue: No ]
  • Reduced postoperative hypocalcemia [ Time Frame: Postoperative week ] [ Designated as safety issue: No ]
  • Improved quality of life [ Time Frame: One year ] [ Designated as safety issue: No ]
  • Improved calcification of bones [ Time Frame: One year ] [ Designated as safety issue: No ]

Estimated Enrollment: 50
Study Start Date: May 2008
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
1: Experimental
Cholecalciferol 2800 IE pr. dag, 52 uger
Drug: Cholecalciferol
2800 IE pr. day in 52 weeks
2: Placebo Comparator
Placebo
Drug: Cholecalciferol
2800 IE pr. day in 52 weeks

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • P-Ca-ion > 1,30 mmol/l
  • P-PTH > 5 pmol/l
  • P-OH25-vitamin D < 80 nmol/l

Exclusion Criteria:

  • P-creatinin > 120 mumol/l
  • usage of Etalpha, Mimpara
  • Cancer
  • Sarcoidosis
  • malabsorption
  • pancreatitis
  • alcohol abuse
  • pregnancy
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00674154

Contacts
Contact: Lars Rolighed, MD lars.rolighed@ki.au.dk
Contact: Lars Rejnmark, MD,PhD,DrMed rejnmark@post6.tele.dk

Locations
Denmark
Osteoporoseklinikken, Aarhus University Hospital, THG Recruiting
Aarhus C, Denmark, 8000
Contact: Lars Rolighed, MD         lars.rolighed@ki.au.dk    
Contact: Lars Rejnmark, MD, PhD         rejnmark@post6.tele.dk    
Principal Investigator: Lars Rolighed, MD            
Sub-Investigator: Lars Rejnmark, MD,PhD,DrMed            
Sub-Investigator: Peter Vestergaard, MD,PhD,DrMed            
Sponsors and Collaborators
University of Aarhus
Investigators
Principal Investigator: Lars Rolighed, MD Unaffiliated
Study Director: Lars Rejnmark, MD,PhD,DrMed Unaffiliated
  More Information

Responsible Party: Unaffiliated ( Lars Rolighed, MD )
Study ID Numbers: PHPT-20080011
Study First Received: May 5, 2008
Last Updated: December 9, 2008
ClinicalTrials.gov Identifier: NCT00674154  
Health Authority: Denmark: The Regional Committee on Biomedical Research Ethics

Keywords provided by University of Aarhus:
Vitamin D
Primary hyperparathyroidism
hypercalcemia

Study placed in the following topic categories:
Vitamin D Deficiency
Cholecalciferol
Parathyroid Diseases
Metabolic Diseases
Avitaminosis
Hyperparathyroidism, primary
Ergocalciferols
Hypercalcemia
Endocrine System Diseases
Vitamin D
Malnutrition
Hyperparathyroidism
Nutrition Disorders
Water-Electrolyte Imbalance
Endocrinopathy
Metabolic disorder
Hyperparathyroidism, Primary
Deficiency Diseases

Additional relevant MeSH terms:
Calcium Metabolism Disorders
Growth Substances
Vitamins
Physiological Effects of Drugs
Bone Density Conservation Agents
Micronutrients
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 16, 2009